Key Points
- Innovation Ltd Panacea sold 80,554 shares of Atara Biotherapeutics on Jan. 12 at an average price of $6.07, raising roughly $488,963 and reducing its stake by 5.73% to 1,324,446 shares.
- Atara beat quarterly EPS estimates (reported ($0.32) vs. ($0.83) expected) with revenue of $3.45M, but analysts still forecast a negative full-year EPS (~-10.39) and the consensus rating is "Reduce" with a $6.00 price target.
- The stock opened at $4.47 with a market cap of $32.23M and a 1‑year range of $4.25–$19.15, and institutional investors own about 70.9% of the shares amid recent position changes by several funds.
Atara Biotherapeutics, Inc. (NASDAQ:ATRA - Get Free Report) major shareholder Innovation Ltd Panacea sold 80,554 shares of the stock in a transaction on Monday, January 12th. The stock was sold at an average price of $6.07, for a total value of $488,962.78. Following the completion of the sale, the insider owned 1,324,446 shares of the company's stock, valued at $8,039,387.22. The trade was a 5.73% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Large shareholders that own more than 10% of a company's shares are required to disclose their transactions with the SEC.
Atara Biotherapeutics Price Performance
Shares of ATRA opened at $4.47 on Thursday. The stock has a market capitalization of $32.23 million, a price-to-earnings ratio of 2.05 and a beta of -0.41. Atara Biotherapeutics, Inc. has a 1 year low of $4.25 and a 1 year high of $19.15. The business's 50 day simple moving average is $14.74 and its 200-day simple moving average is $13.15.
Atara Biotherapeutics (NASDAQ:ATRA - Get Free Report) last released its quarterly earnings results on Wednesday, November 12th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.83) by $0.51. Atara Biotherapeutics had a net margin of 15.40% and a negative return on equity of 41.78%. The company had revenue of $3.45 million for the quarter, compared to the consensus estimate of $2.74 million. On average, sell-side analysts expect that Atara Biotherapeutics, Inc. will post -10.39 earnings per share for the current year.
Institutional Investors Weigh In On Atara Biotherapeutics
Institutional investors have recently added to or reduced their stakes in the business. Marshall Wace LLP acquired a new position in Atara Biotherapeutics during the second quarter worth approximately $327,000. Mackenzie Financial Corp boosted its position in shares of Atara Biotherapeutics by 183.5% during the 3rd quarter. Mackenzie Financial Corp now owns 63,816 shares of the biotechnology company's stock worth $914,000 after purchasing an additional 41,302 shares in the last quarter. Vanguard Group Inc. increased its holdings in Atara Biotherapeutics by 6.6% in the third quarter. Vanguard Group Inc. now owns 203,438 shares of the biotechnology company's stock valued at $2,915,000 after buying an additional 12,677 shares in the last quarter. GSA Capital Partners LLP boosted its position in Atara Biotherapeutics by 33.8% during the third quarter. GSA Capital Partners LLP now owns 26,213 shares of the biotechnology company's stock worth $376,000 after purchasing an additional 6,622 shares in the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in Atara Biotherapeutics in the 2nd quarter valued at approximately $31,000. Hedge funds and other institutional investors own 70.90% of the company's stock.
Wall Street Analyst Weigh In
ATRA has been the topic of several analyst reports. Weiss Ratings reiterated a "sell (d)" rating on shares of Atara Biotherapeutics in a research note on Monday, December 29th. Canaccord Genuity Group reiterated a "hold" rating and set a $6.00 price objective (down from $25.00) on shares of Atara Biotherapeutics in a research note on Tuesday. Finally, New Street Research set a $6.00 price target on Atara Biotherapeutics in a research note on Tuesday. Three research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of "Reduce" and a consensus price target of $6.00.
Get Our Latest Report on Atara Biotherapeutics
Atara Biotherapeutics Company Profile
(
Get Free Report)
Atara Biotherapeutics, Inc is a biotechnology company focused on the discovery, development and commercialization of novel T-cell immunotherapies to transform the treatment of cancer and autoimmune disease. Headquartered in South San Francisco, California, Atara leverages its proprietary off-the-shelf allogeneic Epstein-Barr virus (EBV)-directed T-cell platform to generate engineered cell therapies designed to target EBV-driven malignancies and immune-mediated disorders.
The company's lead product candidate, tabelecleucel, is an off-the-shelf, EBV-specific T-cell therapy in clinical development for the treatment of EBV-positive post-transplant lymphoproliferative disease (PTLD) and other EBV-associated cancers.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
